معرفی
Theo Nettleton is a Research Fellow in Drug Discovery Biology at Monash University, contributing to cutting-edge research in molecular pharmacology and structural biology. His work focuses on G protein-coupled receptors, particularly the glucagon-like peptide-1 (GLP-1) receptor, which plays a key role in diabetes therapeutics.
His research interests lie at the intersection of structural biology, receptor pharmacology, and peptide drug design. By utilizing advanced techniques such as cryo-electron microscopy (cryo-EM), he investigates how dual incretin receptor agonists bind and activate metabolic hormone receptors, offering insights for novel antidiabetic therapies.
The recent publication in his portfolio demonstrates a strong focus on high-resolution structural analysis of peptide-bound GPCRs. This work contributes to understanding the molecular mechanisms underlying incretin-based drugs, with implications for next-generation treatments for type 2 diabetes and obesity.
Scientific Awards:
- No awards listed in the provided text.
Advising and Grants:
There is no explicit information available regarding student supervision or grant funding. However, his involvement in high-impact collaborative research suggests potential participation in major research initiatives within the Drug Discovery Biology program at Monash.
Labs and Research Teams:
Theo Nettleton is part of the Drug Discovery Biology research theme at Monash University, likely collaborating with leading pharmacologists including Professor Denise Wootten and Professor Arthur Christopoulos. This team is renowned for its work on GPCR structure, function, and drug discovery.
